Ceeto Capital Group’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.49M | Buy |
4,000
+160
| +4% | +$109K | 0.68% | 34 |
|
|
2026
Q1 | $2.97M | Hold |
3,840
| – | – | 0.91% | 24 |
|
|
2025
Q4 | $2.96M | Buy |
3,840
+600
| +19% | +$407K | 0.87% | 24 |
|
|
2025
Q3 | $1.82M | Hold |
3,240
| – | – | 0.53% | 40 |
|
|
2025
Q2 | $1.7M | Buy |
3,240
+1,200
| +59% | +$670K | 0.59% | 38 |
|
|
2025
Q1 | $1.29M | Hold |
2,040
| – | – | 0.49% | 46 |
|
|
2024
Q4 | $1.45M | Hold |
2,040
| – | – | 0.53% | 40 |
|
|
2024
Q3 | $2.15M | Buy |
2,040
+500
| +32% | +$556K | 0.8% | 26 |
|
|
2024
Q2 | $1.62M | Buy |
1,540
+500
| +48% | +$485K | 0.63% | 38 |
|
|
2024
Q1 | $1M | Hold |
1,040
| – | – | 0.41% | 59 |
|
|
2023
Q4 | $913K | Hold |
1,040
| – | – | 0.39% | 59 |
|
|
2023
Q3 | $856K | Hold |
1,040
| – | – | 0.41% | 53 |
|
|
2023
Q2 | $747K | Sell |
1,040
-7
| -0.7% | -$5.4K | 0.34% | 64 |
|
|
2023
Q1 | $860K | Buy |
1,047
+7
| +0.7% | +$5.28K | 0.43% | 56 |
|
|
2022
Q4 | $750K | Hold |
1,040
| – | – | 0.41% | 58 |
|
|
2022
Q3 | $716K | Sell |
1,040
-1,000
| -49% | -$629K | 0.41% | 61 |
|
|
2022
Q2 | $1.21M | Sell |
2,040
-500
| -20% | -$325K | 0.66% | 44 |
|
|
2022
Q1 | $1.77M | Hold |
2,540
| – | – | 0.81% | 33 |
|
|
2021
Q4 | $1.6M | Sell |
2,540
-560
| -18% | -$344K | 0.67% | 39 |
|
|
2021
Q3 | $1.88M | Sell |
3,100
-500
| -14% | -$310K | 0.88% | 27 |
|
|
2021
Q2 | $2.01M | Hold |
3,600
| – | – | 0.91% | 31 |
|
|
2021
Q1 | $1.7M | Hold |
3,600
| – | – | 0.83% | 35 |
|
|
2020
Q4 | $1.74M | Hold |
3,600
| – | – | 0.88% | 31 |
|
|
2020
Q3 | $2.02M | Hold |
3,600
| – | – | 1.13% | 17 |
|
|
2020
Q2 | $2.25M | Hold |
3,600
| – | – | 1.45% | 10 |
|
|
2020
Q1 | $1.76M | Hold |
3,600
| – | – | 1.41% | 13 |
|
|
2019
Q4 | $1.35M | Hold |
3,600
| – | – | 0.88% | 32 |
|
|
2019
Q3 | $999K | Sell |
3,600
-150
| -4% | -$44.4K | 0.72% | 42 |
|
|
2019
Q2 | $1.17M | Buy |
3,750
+100
| +3% | +$33.3K | 0.86% | 37 |
|
|
2019
Q1 | $1.5M | Hold |
3,650
| – | – | 1.1% | 23 |
|
|
2018
Q4 | $1.36M | Hold |
3,650
| – | – | 1.13% | 25 |
|
|
2018
Q3 | $1.48M | Buy |
3,650
+150
| +4% | +$57.1K | 1.01% | 27 |
|
|
2018
Q2 | $1.21M | Buy |
3,500
+1,000
| +40% | +$313K | 0.9% | 31 |
|
|
2018
Q1 | $861K | Hold |
2,500
| – | – | 0.65% | 51 |
|
|
2017
Q4 | $940K | Buy |
2,500
+1,000
| +67% | +$405K | 0.67% | 47 |
|
|
2017
Q3 | $671K | Buy |
+1,500
| New | +$714K | 0.5% | 73 |
|
Other funds holding REGN
Ceeto Capital Group's REGN Position: Q2 2026 in Review
Ceeto Capital Group increased its Regeneron Pharmaceuticals (REGN) stake by 4.2% in Q2 2026, buying an estimated $109K and bringing the position to 4,000 shares worth $2.49M. The position accounts for 0.68% of the portfolio, ranked #34.
Ceeto Capital Group first reported a position in REGN in Q3 2017 and has held it in 36 quarters since. The position peaked at $2.97M in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Ceeto Capital Group held 4,000 shares of Regeneron Pharmaceuticals worth $2.49M as of Q2 2026.
- Ceeto Capital Group bought 160 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $109K.
- Regeneron Pharmaceuticals made up 0.68% of Ceeto Capital Group's portfolio in Q2 2026, its #34 holding.
- Ceeto Capital Group first reported a position in Regeneron Pharmaceuticals in Q3 2017 and has held it in 36 quarters since.
- Ceeto Capital Group's Regeneron Pharmaceuticals position peaked at $2.97M in Q1 2026.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Ceeto Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.